Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 7021 results

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

18-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final draft…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationRocheTafinlarUKZelboraf

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

17-09-2014

Privately-held Swiss pharma company Cardiorentis AG has entered into a €45 million ($58.3 million)…

Cardio-vascularCardiorentisFinancialPharmaceuticalSwitzerlandUlaritide

Merck & Co out-licenses tildrakizumab to Sun Pharma

Merck & Co out-licenses tildrakizumab to Sun Pharma

17-09-2014

US pharma giant Merck & Co has entered into an exclusive worldwide licensing agreement with Indian drugmaker…

DermatologicalsGlobalLicensingMerck & CoPharmaceuticalSun Pharmaceuticalstildrakizumab

Synergy Research Group debuts Ukraine Orange Paper

17-09-2014

Synergy Research Group has debuted the Ukraine Orange Paper. The comprehensive report gives the best…

PharmaceuticalResearchSynergy Research GroupUkraine

PTC Therapeutics establishes international headquarters in Dublin, appoints Adrian Haigh head of EMEA

PTC Therapeutics establishes international headquarters in Dublin, appoints Adrian Haigh head of EMEA

17-09-2014

USA-based PTC Therapeutics is to expand its global presence by adding key executives to leadership positions…

BoardroomCNS DiseasesIrelandPharmaceuticalPTC TherapeuticsTranslarna

Room for new products in metastatic prostate cancer treatment market, says GlobalData

Room for new products in metastatic prostate cancer treatment market, says GlobalData

17-09-2014

Although many new products have been launched since 2010 to treat metastatic castration-resistant prostate…

GlobalDataOncologyPharmaceuticalProductionResearchXtandiZytiga

Sanofi and MyoKardia ink deal for genetic heart disease research

Sanofi and MyoKardia ink deal for genetic heart disease research

17-09-2014

French pharma major Sanofi has signed a global collaboration with privately-held US firm MyoKardia to…

Cardio-vascularGlobalLicensingMyoKardiaPharmaceuticalResearchSanofi

Political developments impacting medicines for Russia

Political developments impacting medicines for Russia

17-09-2014

Russia's pharmaceutical market has been growing faster over recent years. The Pharma 2020 Strategy provides…

Markets & MarketingPharmaceuticalPoliticsRussia

FDA approves AstraZeneca’s Movantik for opioid-induced constipation

FDA approves AstraZeneca’s Movantik for opioid-induced constipation

17-09-2014

The US Food and Drug Administration yesterday approved Movantik (naloxegol), an oral treatment for opioid-induced…

AstraZenecaGastro-intestinalsMovantikNektar TherapeuticsPharmaceuticalRegulationUSA

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

16-09-2014

Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today,…

DiabetesNovo NordiskPharmaceuticalResearchTresiba

Nicox acquires ophthalmic company Doliage and Carragelose eyedrops from Marinomed

Nicox acquires ophthalmic company Doliage and Carragelose eyedrops from Marinomed

16-09-2014

French ophthalmic company Nicox has advanced its strategy of building an international business by acquiring…

CarrageloseEuropeMarinomed BiotechnologiesMergers & AcquisitionsNicOxOphthalmicsPharmaceutical

Merck’s odanacatib succeeds in Ph III osteoporosis trial

Merck’s odanacatib succeeds in Ph III osteoporosis trial

16-09-2014

US pharma giant Merck & Co has announced positive data from the pivotal Phase III fracture outcomes study…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalResearchWomen's Health

Empagliflozin/linagliptin combo shows sustained reduction in blood glucose in Ph III

16-09-2014

Family-owned German pharma major Boehringer Ingelheim and US partner Eli Lilly have presented results…

Boehringer IngelheimDiabetesEli LillyempagliflozinlinagliptinPharmaceuticalResearch

Lundbeck launches Brintellix in Denmark

Lundbeck launches Brintellix in Denmark

16-09-2014

Danish CNS drug specialist Lundbeck is debutting its new antidepressant Brintellix (vortioxetine) in…

BrintellixCNS DiseasesDenmarkLundbeckMarkets & MarketingPharmaceutical

Avanir shares jump 85% on positive AVP-923 clinical trial results

Avanir shares jump 85% on positive AVP-923 clinical trial results

16-09-2014

US CNS specialist Avanir Pharmaceuticals has announced positive results from the Phase II clinical trial…

AvanirAVP-923CNS DiseasesPharmaceuticalResearchUSA

Plethora signs licensing agreement with Recordati for premature ejaculation drug

Plethora signs licensing agreement with Recordati for premature ejaculation drug

16-09-2014

Urological specialist Plethora Solutions has signed a licensing agreement with international pharma group…

EuropeLicensingMen's HealthPharmaceuticalPlethoraPSD502Recordati

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

UK M&A regulator consults on more stringent regulations

UK M&A regulator consults on more stringent regulations

16-09-2014

Partly in response to the recent (failed, thus far) attempt by US pharma giant Pfizer to acquire Anglo-Swedish…

LegalMergers & AcquisitionsPfizerPharmaceuticalUK

to-BBB appoints Anders Harfstrand as chief executive

to-BBB appoints Anders Harfstrand as chief executive

15-09-2014

Dutch biopharma company specializing in brain diseases, to-BBB, has appointed Anders Harfstrand as chief…

Anders HarfstrandBoardroomNetherlandsNeurologicalPharmaceutical

FDA accepts Tuzistra XR NDA for full review

FDA accepts Tuzistra XR NDA for full review

15-09-2014

The US Food and Drug Administration has confirmed that the New Drug Application for Tuzistra XR, a prescription…

LicensingPharmaceuticalRegulationRespiratory and PulmonaryTris PharmaTuzistraUSAVernalis

Akashi gets rights to novel DMD treatment from Tonus

Akashi gets rights to novel DMD treatment from Tonus

15-09-2014

US clinical-stage biopharma firm Akashi Therapeutics has acquired global rights to GsMTx-4, a small molecule…

Akashi TherapeuticsGlobalGsMTx-4LicensingPharmaceuticalRare diseasesTonus Therapeutics

Shire gets priority review for its Vyvanse sNDA in binge eating from FDA

Shire gets priority review for its Vyvanse sNDA in binge eating from FDA

15-09-2014

Ireland-headquartered drugmaker Shire has received acceptance for its filing with priority review for…

AbbVieIrelandNeurologicalPharmaceuticalRegulationShireVyvanse

1 to 25 of 7021 results

Back to top